How many investments has H.I.G. HealthBridge Partners made?

H.I.G. HealthBridge Partners has 26 tracked investments, 1 of which have exited via acquisition or IPO.

What stage does H.I.G. HealthBridge Partners invest at?

H.I.G. HealthBridge Partners invests at the Growth stage.

What is H.I.G. HealthBridge Partners's typical check size?

H.I.G. HealthBridge Partners typically writes checks of $5M – $40M.

What sectors does H.I.G. HealthBridge Partners focus on?

H.I.G. HealthBridge Partners focuses on Biotech, Digital Health, Healthtech, Medical Devices.

Where is H.I.G. HealthBridge Partners located?

H.I.G. HealthBridge Partners is headquartered in Miami, US.

Who does H.I.G. HealthBridge Partners co-invest with?

H.I.G. HealthBridge Partners most often shares deals with H.I.G. Capital, Corewell Health Ventures, SV Health Investors, among 36 tracked co-investors.

H.I.G. HealthBridge Partners

Growth equityoperating company · company profile

Miami · Growth · 15 people tracked

★ Follow + Add to CRM ⤳ Find an introduction

✨ Fox Verdict

Investment thesis

H.I.G. HealthBridge Capital Partners is a growth equity fund focused on growth-stage healthcare companies, aiming to improve patient outcomes while lowering the total cost of healthcare. Its investment team brings experience across pharma, biotech, medical devices, diagnostics, and related services. Operating as part of the broader H.I.G. platform with extensive resources, the firm partners with founders and management teams to drive operational improvements and build market-leading positions. It emphasizes value creation, working alongside portfolio company leadership to establish stronger, more successful businesses across a range of healthcare-related sectors.

Invests inBiotech Digital Health Healthtech Medical Devices Asia-Pacific Europe Global Latin America Miami Middle East & North Africa North America United States

Source: firm website, verified Aug 3, 2026.

Stage

Growth

Check

$5M – $40M

Miami, Florida, US

Instruments

Equity

Founded

1993

AUM

$75B

Tracked investments

Team · 15 people

from the firm's website & curated & public directories

Sami Mnaymneh· Founder and Executive Chairman

Sami Mnaymneh is a Founder and Executive Chairman of H.I.G., which he co-founded in 1993 and led as CEO until 2026, and he approves the firm's capital commitments. Before H.I.G., he was a Managing Director at The Blackstone Group and began his career at Morgan Stanley in New York. He holds a B.A. from Columbia University and a J.D. and M.B.A. from Harvard Law School and Harvard Business School.

Tony Tamer· Founder and Executive Chairman· Miami, Florida, United Statesin

Tony Tamer is a Founder and Executive Chairman of H.I.G. Capital, which he helped establish in 1993, and he approves the firm's capital commitments. Before H.I.G., he was a partner at Bain & Company and has worked with early-stage and middle-market companies. He earned a B.S. from Rutgers University, an M.B.A. from Harvard Business School, and an M.S. in Electrical Engineering from Stanford University.

Alex Zisson· Managing Director

a•••@higcapital.comreveal

Gwen Watanabe· Managing Director

g•••@higcapital.comreveal

Conor Coleman· Managing Director, Head of U.S. Portfolio Operations· Washington, District of Columbia, United Statesin

Hans Sherman· Managing Director· Boston, Massachusettsin 𝕏

Hans Sherman is an investor at H.I.G. Growth Partners, where he works across the full investment process including origination, structuring, financing, and post-closing growth and operational strategy. He has more than 15 years of investing experience spanning cloud infrastructure, cybersecurity, horizontal and vertical SaaS, and internet and digital marketing. Before H.I.G., he was a Partner at Bain Capital Tech Opportunities and a Vice President in Goldman Sachs' Merchant Banking Division, and started his career at Summit Partners; he holds a B.A. from Vanderbilt University and an M.B.A. from UCLA Anderson.

Mark Fiske· Managing Director, AI & Commercial· New York City Metropolitan Areain

Michael Mann· Managing Director, AI & Commercial· Dallas, Texas, United Statesin

Mike Leamer· Managing Director, Head of U.S. Portfolio Operations· New York, New York, United Statesin

Steven Wastie· Operating Partner· Menlo Park, California, United Statesin

Steven Wastie is an Operating Partner at H.I.G. Capital with experience in go-to-market strategy, marketing operations, and scaling companies across global markets. His background includes leadership roles in demand generation, marketing technology, and business development, with involvement in multiple company exits and category leadership positions. His skill set encompasses communications strategy, marketing automation, AI applications, and team building from early stage through 50+ person organizations.

Dylan Harmon· Principal

d•••@higcapital.comreveal

Brian Schwartz· CEO

Brian Schwartz is the Chief Executive Officer of H.I.G. Capital, where he sets the firm's strategic direction and serves on its Executive Committee. He joined H.I.G. in 1994 and has held senior leadership roles across the firm's Private Equity, Credit, and Real Assets platforms, including six years as Co-President. Earlier in his career he worked in strategic planning at PepsiCo and investment banking at Dillon, Read & Co., and he holds a B.S. from the University of Pennsylvania and an M.B.A. from Harvard Business School.

Douglas Berman· Co-President

Douglas Berman is Co-President of H.I.G. Capital, which he joined in 1996 and where he has been an Executive Managing Director since 2007. Earlier in his tenure he led the acquisition of more than 40 businesses for the firm. Before H.I.G., he worked as a consultant at Bain & Company. He holds a B.A. in Economics from the University of Virginia and an M.B.A. from The Wharton School of the University of Pennsylvania.

Rick Rosen· Co-President· Miami, Florida, United Statesin

Rick Rosen is Co-President of H.I.G. Capital, where he helps direct the firm's day-to-day operations and serves on the investment committees for all H.I.G. funds. He has more than 25 years of private equity and M&A experience and joined H.I.G. in 1998, having held leadership roles across several of the firm's funds. Before H.I.G., he worked at General Electric Company and GE Capital, including on the GE Corporate Finance Staff, and holds a B.S. in Economics from Stanford University and an M.B.A. from Harvard Business School.

Bruce Robertson· Senior Advisor· Miami

Senior Advisor at H.I.G. HealthBridge Partners focused on life sciences investments across biopharmaceuticals, medical devices, and diagnostics, with more than 30 years in the sector. Previously Managing Director at Toucan Capital and General Partner at GIV Venture Partners, with earlier roles at IGEN International and W.R. Grace & Co.; he holds degrees from the University of Pennsylvania, University of Delaware, and Harvard Business School.

b•••@higcapital.comreveal

What they invest in

from 21 of 27 portfolio companies

Healthtech ×17Biotech ×14Medical Devices ×10Digital Health ×5Hardware ×2Advanced Manufacturing ×1Consumer ×1Data & Infrastructure ×1

HQs:United States×15Canada×1Switzerland×1

Who they back

founder profiles across 8 portfolio companies

50%

solo founders

4 of 8 mapped founding teams

Founding team size:solo founder×42 founders×4

Investments · 27 tracked

founders shown can be your intro path

By year:2020 · 1 2018 · 1 2014 · 1 2013 · 14 dated

Exagenexagen.com in 𝕏NASDAQ: XGN

Exagen develops diagnostic and monitoring tests for autoimmune diseases, including tools to distinguish connective tissue disease and assess lupus prognosis and progression.

BiotechDigital HealthHealthtechMedical DevicesVista, US

Thierry Dervieux(Executive Officer)inWendy Swedick(Executive Officer)Fortunato R. Rocca(Executive Officer, Director)

BoardJames L.L. Tullis(Director)inBrian Birk(Director)Ebetuel Pallares(Director)

Co-investorsCottonwood Technology Fund EPIC VENTURES H.I.G. Capital Sun Mountain Capital Tullis Health Investors Tullis

Rxsightrxsight.com in 𝕏NASDAQ: RXST

RxSight develops the Light Adjustable Lens (LAL), an FDA-approved intraocular lens that surgeons can adjust after cataract surgery to fine-tune a patient's prescription once the eye has healed.

HealthtechMedical DevicesPasadena, US

Robert H. Grubbs(Director)Daniel M. Schwartz(Director)D. Verne Sharma(Executive Officer, Director)Richard Drinkward(Executive Officer)in

BoardJavier Perez-Sala(Director)Jan Bonel(Director)

Co-investorsFlying L Partners Foresite Capital H.I.G. Capital Longitude Capital RA Capital Visionary Ventures +1 more

Neurana PharmaceuticalsDec 2013SEC filingmedium confidence

Developing a novel treatment for acute muscle spasms.

BiotechSan Diego, US

Kathleen D. Scott(Chief Financial Officer, Secretary and Treasurer)Judy Caron(Chief Operating Officer)David F. Hale(Chairman of the Board of Directors, Acting President and CEO)Brian Dorsey(Director)Daniel Becker(Director)Joshua Richardson(Director)

Board seatAlex Zisson· per SEC Form D · $3.8M raise · filed May 2018

Co-investorsSofinnova Ventures Longitude Capital

Alder BiopharmaceuticalsJan 2018

BiotechBothell, US

Randall Schatzman(Executive Officer, Director)Jeffrey Smith(Executive Officer)James Bucher(Executive Officer)Randal Hassler(Executive Officer)Elisabeth Sandoval(Executive Officer)

BoardHeather Preston(Director)

Co-investorsH.I.G. Capital

Arvelle Therapeuticsangelinipharma.ch in

Angelini Pharma Switzerland is the Swiss arm of a pharmaceutical company focused on brain health and epilepsy, offering prescription treatments for patients and healthcare professionals.

BiotechConsumerHealthtechZug, CH

Co-investorsAndera Partners F-Prime Capital H.I.G. Capital

Augmedicsaugmedics.com in 𝕏Jun 2020

Augmedics develops augmented reality surgical navigation technology aimed at improving outcomes in spine surgery.

HardwareHealthtechMedical DevicesArlington Heights, US

Nissan Elimelech(Chief Executive Officer)

Co-investorsAlmeda Ventures Evidity Health Capital H.I.G. Capital Partners Resolute XR Invest

BIOVECTRAbiovectra.com in 𝕏

BIOVECTRA is a contract development and manufacturing organization (CDMO) with research and development capabilities in biologics process development, complex chemistry, and analytical development.

Advanced ManufacturingBiotechHealthtech

Co-investorsH.I.G. Capital

Celerioncelerion.com in

Celerion is a contract research organization specializing in early phase clinical drug development, providing bioanalytical services and laboratory testing that generate clinical data for pharmaceutical clients.

BiotechDigital HealthHealthtechMedical DevicesLincoln, US

Co-investorsH.I.G. Capital SV Health Investors

Click Therapeuticsclicktherapeutics.com in 𝕏

Click Therapeutics develops, validates, and commercializes software-based prescription medical treatments, including software-enhanced drug products that combine digital therapeutics with pharmacotherapy.

BiotechDigital HealthHealthtechMedical DevicesNew York, US

David B. Klein(Founder and CEO)inDavid Klein(Executive Officer, Director)inRandall Stanicky(Executive Officer)in

BoardAlex Zisson(Director)Lee Shapiro(Director)inCris De Luca(Director)in

Co-investorsAccelmed Partners H.I.G. Capital Health Catalyst Capital Hikma Ventures Sanofi Ventures Supernode Ventures +2 more

Cookie Policyhig.com in 𝕏

H.I.G.

Enterprise Software

Co-investorsH.I.G. BioHealth Partners

ForSight VISION5Apr 2014

HealthtechMenlo Park, US

Eugene de Juan, Jr., M.D.(Director)K. Angela Macfarlane(Executive Officer, Director)John F. Maroney(Executive Officer, Director)

BoardRobert C. Bellas, Jr.(Director)Hanson S. Gifford III(Executive Officer, Director)Jim Glasheen(Director)

Co-investorsH.I.G. Capital Lightstone Ventures Versant Ventures

Highridgehighridgemedical.com in

Highridge Medical presents itself as a medical company built on a history of product innovation, led by an executive leadership team.

HardwareHealthtechMedical Devices

Co-investorsCorewell Health Ventures H.I.G. Capital

HyperBranch

Develops innovative medical devices for ophthalmology, general, and specialty surgery markets.

Co-investorsH.I.G. Capital

Intact Vascularintactvascular.com

BiotechHealthtechWayne, US

Robert Giasolli(Executive Officer)Bruce J. Shook(Executive Officer, Director)Carol Burns(Executive Officer)Marc Penna(Executive Officer)Monica Klos(Executive Officer)Michael Longo(Executive Officer)

Co-investors415 Capital H.I.G. Capital Runway Growth Capital H.I.G. BioHealth Partners New Enterprise Associates (NEA)Vensana Capital

Leitersleiters.com in

Leiters Health is an FDA-registered 503B outsourcing facility that produces sterile compounded preparations for hospitals, surgery centers, and ophthalmic use.

BiotechHealthtechMedical DevicesDenver, US

Co-investorsCorewell Health Ventures Escalate Capital Partners Frazier Healthcare Partners H.I.G. Capital Kaiser Permanente Ventures Rex Health Ventures +2 more

Navitas Life Sciencesnavitaslifesciences.com in

Navitas Life Sciences is a global clinical research partner providing clinical, regulatory, safety, and data management solutions to pharmaceutical, biotech, and federal agencies for drug development and patient safety.

BiotechData & InfrastructureDigital HealthHealthtechMedical Devices

Srinivasan H.R.(Chief Executive Officer)

Co-investorsH.I.G. Capital

NeuWave

Develops and commercializes energy-based soft tissue ablation devices for various clinical markets.

Co-investorsH.I.G. Capital

Nevakarnevakar.com

BiotechBridgewater, US

Navneet Puri(Executive Officer)

Co-investorsH.I.G. Capital

Novadaq

Develops and commercializes medical devices based on a proprietary imaging platform for diagnosis and treatment of diseases.

Co-investorsH.I.G. Capital

On Target Laboratoriesontargetlabs.com in 𝕏

On Target Laboratories is a company of scientists and researchers focused on cancer surgery, developing products to support surgical oncology.

BiotechHealthtechMedical Devices

Bill Peters(President, Chief Executive Officer, and Board Member)Rod MacLeod(Chief Financial Officer)Tommy Lee(Senior Vice President of Clinical Operations)Catherine Brisson(Vice President of Regulatory Affairs and Quality)Anne Fornicola(Vice President of Chemistry, Manufacturing and Controls)Scott Huennekens(Executive Chairperson)

Co-investors3B Future Health Fund Cerity Partners Ventures Elevate Ventures H.I.G. Capital

Orbus Therapeuticsorbustherapeutics.com

Orbus Therapeutics is a clinical-stage biopharmaceutical company developing eflornithine (DFMO), an oral ODC inhibitor, as a cancer therapy.

BiotechHealthtechAptos, US

Jason Levin(Founder, Director and Chief Executive Officer)Robert M. Myers(Executive Officer, Director)

BoardMichael Wasserman(Director)Patrick Enright(Director)Elisha (Terry) Gould(Director)Ernest Mario(Director)

Co-investorsH.I.G. Capital Longitude Capital Agent Capital

Quinnova Pharmaceuticalsquinnova.com

Specialty pharmaceutical company built on patent-protected dermal delivery technologies.

Co-investorsH.I.G. Capital

Rising Pharmaceuticalsrisingpharma.com in

Develops and markets generic and specialty branded pharmaceutical products, based in New Brunswick, NJ.

Co-investorsH.I.G. Capital

Salmedixacquired by Cephalon Inc

Develops oncology drugs for hematologic cancers; acquired by Cephalon Inc. in 2005.

Co-investorsH.I.G. Capital

Taconic Biosciencestaconic.com in 𝕏

Taconic Biosciences provides genetically engineered mouse and rat models, humanized immune system mice, custom model generation, colony management, and in vivo research services.

BiotechDeep TechHealthtech

Co-investorsH.I.G. Capital

VertiFlex

HealthtechSan Clemente, US

Jeff Swiecki(Executive Officer)Earl R. Fender(Executive Officer, Director)Robert Reitzler(Executive Officer)Scott C. Lynch(Executive Officer)Jeffrey A. Swiecke(Executive Officer)Anthony G. Mauriello(Executive Officer)

Co-investorsH.I.G. Capital Alta Partners

WellTheoryzerigohealth.com in 𝕏

Zerigo Health develops technology-driven digital therapeutics and care solutions for individuals living with chronic skin conditions.

Digital HealthHealthtechMedical Devices

Co-investors7wire Ventures Corewell Health Ventures H.I.G. Capital SV Health Investors Accel General Catalyst +3 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

Exits · 3

IPOs and acquisitions across the tracked portfolio

ExagenNASDAQ: XGNRxsightNASDAQ: RXSTSalmedixacq. by Cephalon Inc

Portfolio news

latest coverage across their companies

RxSight’s Long-Term Lens Study: What Ongoing Results Could Mean For RXST Investors - TipRanks.com

Rxsight · tipranks.com · Aug 12, 2026

XGN Initiates Coverage On Exagen -- Roth Capital Assigns Buy Rating

Exagen · gurufocus.com · Jun 25, 2026

Celerion Receives Investment From THL Partners

Celerion · finsmes.com · Apr 23, 2026

Click Therapeutics raises $50M and more funding news | MobiHealthNews

Click Therapeutics · mobihealthnews.com · Apr 17, 2026

Who is Michael Leiters, potential new CEO of Porsche? | Reuters

Leiters · reuters.com · Oct 17, 2025

WellTheory Raises $14M in Series A Funding

WellTheory · finsmes.com · Oct 15, 2025

Frequently asked questions

How many investments has H.I.G. HealthBridge Partners made?: H.I.G. HealthBridge Partners has 26 tracked investments, 1 of which have exited via acquisition or IPO.
What stage does H.I.G. HealthBridge Partners invest at?: H.I.G. HealthBridge Partners invests at the Growth stage.
What is H.I.G. HealthBridge Partners's typical check size?: H.I.G. HealthBridge Partners typically writes checks of $5M – $40M.
What sectors does H.I.G. HealthBridge Partners focus on?: H.I.G. HealthBridge Partners focuses on Biotech, Digital Health, Healthtech, Medical Devices.
Where is H.I.G. HealthBridge Partners located?: H.I.G. HealthBridge Partners is headquartered in Miami, US.
Who does H.I.G. HealthBridge Partners co-invest with?: H.I.G. HealthBridge Partners most often shares deals with H.I.G. Capital, Corewell Health Ventures, SV Health Investors, among 36 tracked co-investors.

Images

Similar investors

B Capital Group

B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.

$10M – $50M

Breyer Capital

Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.

$500K – $10M

DCVC (Data Collective)

DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.

$5M – $25M

Eight Roads Ventures

Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.

$5M – $30M

GV (Google Ventures)

GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.

$250K – $50M

Featured in lists

Investors & VC Firms in North America Investors & VC Firms in United States Investors & VC Firms in Europe Growth Investors & VC Firms Investors & VC Firms in Global Investors & VC Firms in Asia-Pacific Healthtech Investors & VC Firms Growth Investors & VC Firms in North America Healthtech Investors & VC Firms in North America Biotech Investors & VC Firms Healthtech Investors & VC Firms in United States Growth Investors & VC Firms in United States